BioCentury | Oct 17, 2020
Regulation

CHMP’s October recommendations

...from Aimmune Therapeutics Inc. (NASDAQ:AIMT) for peanut allergy; and a label extension for psoriatic arthritis for Tremfya guselkumab...
...GSK2696274) lumasiran (ALN-GO1) inclisiran (aln-pcssc, pcsk9si) Palforzia, peanut allergen powder (AR101, arc001, peanut allergy oral immunotherapy (oit)) Tremfya, guselkumab (CNTO 1959) Blincyto...
BioCentury | Aug 19, 2020
Deals

Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

...“$500M Up Front”).The pharma’s immunology drugs include Remicade infliximab, Simponi golimumab, Stelara ustekinumab and Tremfya guselkumab...
BioCentury | Jul 16, 2020
Regulation

July 15 Quick Takes: Early access in U.K. for Alnylam RNAi; plus Verrica, CytoDyn, J&J and Roche

...Tremfya The Janssen Pharmaceutical Cos. unit of Johnson & Johnson (NYSE:JNJ) said FDA approved Tremfya guselkumab...
BioCentury | Dec 27, 2019
Company News

With Zejula’s third local approval, Zai ready for mainland China launch

...submissions by year end. Zai gained $2.02 to $40.25 on Friday. NMPA also approved Tremfya guselkumab...
...Johnson & Johnson (NYSE:JNJ) and a chickenpox vaccine from Sinovac Biotech Ltd. (NASDAQ:SVA) on Friday. Tremfya...
BioCentury | Aug 13, 2019
Clinical News

Taltz tops Tremfya in psoriasis but data may not change prescribing habits

...inhibitors like Taltz ixekizumab could be the best bet over IL-23 inhibitors such as Tremfya guselkumab...
...69.1%, p=0.127). But by week 48, the numbers favored Tremfya, with 84.5% of patients receiving Tremfya...
...adalimumab (D2E7) Skyrizi, risankizumab (ABBV-066, BI 655066) Taltz (Brand), LY2439821 (Compound #), ixekizumab (Generic), Taltz (Other) Tremfya, guselkumab (CNTO 1959) AbbVie...
BioCentury | Aug 9, 2019
Tools & Techniques

The next frontier for single-cell analysis

...to interrogate thousands of samples acquired in Janssen’s 200-patient VEGA trial of anti-IL-23A mAb Tremfya guselkumab...
BioCentury | Jun 14, 2019
Clinical News

June 14 Clinical Quick Takes: Chi-Med, BeiGene, UCB, Global Blood and more

...EULAR) meeting in Madrid. Tremfya meets in Phase III psoriatic arthritis trials Janssen said Tremfya guselkumab...
BioCentury | Feb 1, 2019
Company News

Novartis plots new course for Sandoz

...of multiple competitor entries and new competitor data." In December, Janssen Biotech Inc. said Tremfya guselkumab...
...efficacy in treating moderate-to-severe plaque psoriasis compared with Cosentyx in a head-to-head Phase III trial. Tremfya...
...frequent dosing than Cosentyx and no signs of de novo inflammatory bowel disease (IBD) (see "Tremfya...
BioCentury | Jan 31, 2019
Company News

Novartis plots new course for Sandoz

...of multiple competitor entries and new competitor data." In December, Janssen Biotech Inc. said Tremfya guselkumab...
...efficacy in treating moderate-to-severe plaque psoriasis compared with Cosentyx in a head-to-head Phase III trial. Tremfya...
...frequent dosing than Cosentyx and no signs of de novo inflammatory bowel disease (IBD) (see "Tremfya...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
Items per page:
1 - 10 of 67